Next Article in Journal
The Price of Innovation—The Role of Drug Pricing in Financing Pharmaceutical Innovation. A Conceptual Framework
Previous Article in Journal
Disparities of Health Service for the Poor in the Coastal Area: Does Universal Health Coverage Reduce Disparities?
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

President Trump’s Prescription to Reduce Drug Prices: From the Campaign Trail to American Patients First

by
Monique Dabbous
1,*,
Clément François
2,
Lylia Chachoua
3 and
Mondher Toumi
1
1
Public Health Department - Research Unit EA, Aix-Marseille Université, Marseille, France
2
Creativ-Ceutical, Paris, France
3
Market Access Society, Paris, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2019, 7(1), 1579597; https://doi.org/10.1080/20016689.2019.1579597
Submission received: 24 August 2018 / Revised: 23 January 2019 / Accepted: 25 January 2019 / Published: 4 March 2019

Abstract

Background: Drug prices in the United States are the highest in the world, restricting access to the domestic lower income population. President Trump campaigned heavily on promises to reduce drug prices. Methods: A literature review was conducted through PUBMED, EMBASE, Media and grey literature to consolidate and analyze publications addressing President Trump’s promises from the campaign trail as well as the shortcomings and achievements of the Trump administration. Results: Major promises ranged from repealing and replacing Obamacare, expanding coverage, allowing cross-state insurance purchasing, and reducing drug prices. Main accomplishments of the Trump administration have been two executive orders (13765 and 13813), the proposition of the American Health Care Act, and the passing of the Tax Cuts and Jobs Act of 2017. The American Patients First blueprint further revealed the administration’s strategies for lowering drug prices. The administration has also engaged in unconventional strategies, such as via bilateral leverage directly with trade partners. Conclusion: The Trump administration has not yet been able to fulfill the major campaign promises, primarily the ones requiring legislative and/or administrative action. If enough legislative action is accomplished to implement the Trump administration’s promises, the effects on the pharmaceutical industry could be direct, yet minimal, unless Medicare can directly negotiate with manufacturers.
Keywords: President Trump; drug prices; American Patients First (APF); campaign; Trump administration President Trump; drug prices; American Patients First (APF); campaign; Trump administration

Share and Cite

MDPI and ACS Style

Dabbous, M.; François, C.; Chachoua, L.; Toumi, M. President Trump’s Prescription to Reduce Drug Prices: From the Campaign Trail to American Patients First. J. Mark. Access Health Policy 2019, 7, 1579597. https://doi.org/10.1080/20016689.2019.1579597

AMA Style

Dabbous M, François C, Chachoua L, Toumi M. President Trump’s Prescription to Reduce Drug Prices: From the Campaign Trail to American Patients First. Journal of Market Access & Health Policy. 2019; 7(1):1579597. https://doi.org/10.1080/20016689.2019.1579597

Chicago/Turabian Style

Dabbous, Monique, Clément François, Lylia Chachoua, and Mondher Toumi. 2019. "President Trump’s Prescription to Reduce Drug Prices: From the Campaign Trail to American Patients First" Journal of Market Access & Health Policy 7, no. 1: 1579597. https://doi.org/10.1080/20016689.2019.1579597

Article Metrics

Back to TopTop